SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout!
LGND 193.07-1.2%Dec 3 3:59 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: WTDEC who wrote (18343)3/31/1998 9:25:00 PM
From: celeryroot.com  Read Replies (2) of 32384
 
of interest from 10k:

" AMENDMENT #2 TO OPTION AND WHOLESALE PURCHASE AGREEMENT

This Amendment is executed as of the 16th day of March, 1998 by and between
Eli Lilly and Company ("Lilly") and Ligand Pharmaceuticals Incorporated
("Ligand").

Whereas, Lilly and Ligand have entered into an Option and Wholesale
Purchase Agreement dated as of November 25, 1997, and amended on February 23,
1998 (the "Agreement"), and

Whereas the parties now desire to amend the Agreement to extend the period
of time pursuant to which Ligand may exercise the Ligand Option (as defined in
the Agreement).

Now, therefore, in consideration of the foregoing, the mutual covenants set
forth below and other consideration, receipt sufficiency of which are hereby
acknowledged, the parties agree as follows:

1. Section 1.1 of the Agreement is hereby amended to read in its
entirety as follows:

"Ligand Option. Until the date that is seven (7) days after the date on which
Lilly gives written notice (the "Option Termination Notice") to Ligand of
Lilly's desire to terminate the Ligand Option (the "Ligand Option Period"),
Ligand shall have the option (the "Ligand Option") to become Lilly's exclusive
wholesaler of the Products, subject to the terms and conditions contained in
this Agreement. Lilly shall not give the Option Termination Notice prior to
April 27, 1998. If Lilly gives the Option Termination Notice prior to May 28,
1998, it will, upon written request made by both Ligand and Seragen and
delivered to Lilly within five (5) days of the date of the Option Termination
Notice, defer effectiveness of the Option Termination Notice until May 28, 1998,
(with the effect that the Ligand Option would expire on June 4, 1998, if not
previously exercised). ***
***
***
***
***
***

2. All other terms and conditions of the Agreement shall remain in full
force and effect.

3. This Amendment may be executed in two or more counterparts, each of
which shall be deemed an original, but all of which together shall constitute
one in the same.

LIGAND PHARMACEUTICALS INC. ELI LILLY AND COMPANY

By: /s/ William L. Respess By: /s/ August M. Watanabe
--------------------------- -----------------------------
Sr. Vice President, General August M. Watanabe
Counsel, Government Affairs Executive Vice President
Science and Technology

Date: February 28, 1998 Date: February 28, 1998
----------------- -----------------

The numbers are quite good if you take away the 65mil technology write off
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext